Thales and Intel Enable Advanced Protection for the Google Cloud Ecosystem
Thales, the leading global technology and security provider, today announced a collaboration leveraging its CipherTrust Data Security Platform (CDSP) to support End-To-End Data Protection (E2EDP) on Google Cloud, using Confidential Computing (CC) from Google Cloud and trusted cloud independent attestation provided by Intel Trust Authority (ITA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410848317/en/
©Thales
The effort is a step forward in data security, giving enterprises additional controls to protect their data at rest, in transit, and in use.
“As more enterprises migrate their data and workloads to the cloud, there is an increasing demand to safeguard the privacy and integrity of the data, especially those sensitive workloads that include intellectual property, AI models and valuable personal information. This collaboration enables enterprises to protect and control their data at rest, in transit and in use with fully verifiable attestation. Our close collaboration with Google Cloud and Intel increases our customers' trust in their cloud migration,” said Todd Moore, Vice President of Data Security Products at Thales.
A majority of the 2023 Thales Cloud Security Study respondents reported having a significant amount of sensitive data stored and in use in the cloud. Consequently, safeguarding sensitive data and associated workloads when stored or in use, is an increasing priority, especially for highly regulated industries such as financial services and healthcare. Thales's collaboration with Intel and Google Cloud provides certifiable controls for enterprises to fully protect their data end-to-end.
Purnam Sheth, Vice President and General Manager: Trust and Security Products, SATG at Intel: “Creating this groundbreaking, seamless data security platform in Google Cloud meets customers’ complex requirements for data protection, controlled access and security, and adherence to compliance for data at rest, in transit and in use. Foundational Intel® Trust Domain Extensions Confidential Compute and Intel® Trust Authority gives enterprises assurance of the integrity of their workloads and guards at all stages of data management. This valuable collaboration between Thales, Google Cloud and Intel makes this possible.”
This security platform is based on the principle of separation of duties, where the customer remains in control of the encryption keys and their location. This approach enhances trust by holding each stakeholder responsible for their respective roles and reduces the ability for a malicious actor to access code and data at rest, in transit and while being executed.
Customers can migrate existing workloads with sensitive data or create new workloads needing zero trust, confidential computing and Confidential AI to this security platform in Google Cloud to broaden data security, attestation and set the right authorizations. With end-to-end data protection, multiple parties can securely collaborate on various use cases, such as Confidential AI datasets and models as needed while preserving privacy, confidentiality, and compliance with privacy regulations.
The Thales CipherTrust Data Security Platform uses Intel Trust Authority as a zero-trust, independent attestation service for advanced security and scalable confidential computing. Consistent attestation to Trusted Execution Environments (TEE) that are based on Intel Trust Domain Extensions. This single, consistent attestation process provides assurance to any relying party that the TEE and any data and workloads running within it have not been compromised.
Brian Roddy, VP, Product Management, Google Cloud: “Google Cloud is committed to providing our customers secure, private and reliable environments for their workloads, and our Confidential Computing portfolio plays a critical role in this effort. Offering our customers solutions like Thales’ encryption key management expertise, combined with Intel’s Trust Authority attestation, enables the choice of even stronger privacy controls.”
The collaboration comes as Thales is recognized for its achievements in the Google Cloud ecosystem. For the second year in a row, Thales has received the 2024 Google Cloud Technology Partner of the Year Award for Security - Data Protection.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Artificial Intelligence, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410848317/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity28.11.2024 17:44:00 CET | Press Release
Please replace the release dated November 21, 2024 with the following corrected version due to multiple revisions. The updated release reads: ALTASCIENCES SUPPORTS METSERA IN THEIR EARLY-STAGE CLINICAL TRIALS FOR OBESITY Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable, fully biased GLP-1 receptor agonist. In September, Metsera reported positive topline results from the clinical trial conducted at Altasciences’ facility, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the final dose) and a 380-hour half-life. This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i. In addition to clinical conduct, Altasciences supported Me
MAG Group Holding Real Estate Portfolio Reaches USD 11.9 Billion28.11.2024 11:47:00 CET | Press Release
MAG Group Holding, the multinational conglomerate incorporating different companies serving diverse sectors, announced its portfolio of current and under development projects across its different real estate subsidiaries has reached USD 11.9 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128995871/en/ Moafaq Al Gaddah, Founder and Chairman of MAG Group Holding (Photo: AETOSWire) MAG Group Holding’s real estate subsidiaries include MAG Lifestyle Development, Keturah, Invest Group Overseas (IGO), MBL, Shoumous, Art of Living Mall and MAG Leasing for warehouses. In his comments, Moafaq Al Gaddah, Founder and Chairman of MAG Group Holding, said: "The UAE's real estate sector is witnessing unprecedented demand, driven by the strategic vision and initiatives of our wise leadership. The government’s ongoing efforts to foster a favorable investment climate have made the UAE a preferred investment destination for global i
Dev4All and Pharmaseed Join Forces in Commercial Cooperation to Boost Preclinical Development Services28.11.2024 07:30:00 CET | Press Release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127719655/en/ Dev4All and Pharmaseed Join Forces in Commercial Cooperation (Graphic: Business Wire) Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research Organization (CRO) with over 20 years of expertise in preclinical drug development. This partnership combines the strengths of both organizations to offer an integrated, end-to-end approach for preclinical development. Together, Dev4All and Pharmaseed aim to deliver comprehensive and competitive solutions that accelerate drug development and address the complexities of today’s R&D landscape. With over two decades of experience in CRO services and ten years advancing drug development candidates from TRL3 to TRL5, this close cooperation provides tailored preclinical support, cutting-edge laboratory capabilities, and strategic expert
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis28.11.2024 07:00:00 CET | Press Release
Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published inJAMA Dermatology.1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving placebo at Week 16, with a rapid and clinically meaningful response on itch and sleep disturbance observed as early as Week 4.1 Nemolizumab was well-tolerated, and its safety profile was generally consistent with previous studies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127699136/en/ “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent U.S. Food and Drug Administration approval for the treatment of adults with prurigo nodul
After Three Successful Years With the IBSA Class40 and Skipper Alberto Bona, IBSA’s Sports Project Comes to an End27.11.2024 15:30:00 CET | Press Release
Three years of intense work, 25,000 miles of racing, five Atlantic crossings, ten regattas, a first and a fourth place in the international Class40 circuit, five podium finishes and two victories: a remarkable human and sporting achievement that combined tenacity, courage, adventure, sustainability and inclusion. This marks the conclusion, after three sporting seasons, of the project that united the multinational pharmaceutical company IBSA with ocean sailor Alberto Bona. An intense journey that began in 2022 with the construction of the Class40 IBSA in France and touched the shores of Brittany, Normandy, England, Ireland, Martinique and Guadeloupe, the United States and Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127852350/en/ “We experienced three intense years, during which we took the IBSA brand around the world; a sporting project that allowed ingenuity, courage, perseverance and passion to fully manifest”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom